Caxton Associates LLP Makes New Investment in Insmed, Inc. $INSM

Key Points

• Caxton Associates LLP acquired a new stake of 5,785 shares in Insmed, Inc., valued at approximately $441,000, during the first quarter according to its latest 13F filing.
• Wall Street analysts are optimistic about Insmed, with Morgan Stanley and Truist Financial raising their price targets to $144.00 and $139.00 respectively, while maintaining favorable ratings.
• CEO William Lewis and COO Roger Adsett recently sold significant shares of Insmed stock, indicating insider selling activity, with the CEO's sale totaling around $881,466.

Caxton Associates LLP bought a new stake in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 5,785 shares of the biopharmaceutical company's stock, valued at approximately $441,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Cullen Frost Bankers Inc. boosted its stake in Insmed by 164.9% during the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 221 shares during the period. Elequin Capital LP bought a new stake in shares of Insmed in the 4th quarter worth approximately $28,000. NBC Securities Inc. bought a new stake in shares of Insmed in the 1st quarter worth approximately $49,000. Versant Capital Management Inc lifted its position in shares of Insmed by 546.3% in the 1st quarter. Versant Capital Management Inc now owns 698 shares of the biopharmaceutical company's stock worth $53,000 after acquiring an additional 590 shares during the period. Finally, Signaturefd LLC lifted its position in shares of Insmed by 60.0% in the 1st quarter. Signaturefd LLC now owns 867 shares of the biopharmaceutical company's stock worth $66,000 after acquiring an additional 325 shares during the period.

Insmed Price Performance

INSM stock traded up $1.08 during midday trading on Thursday, reaching $145.86. 1,835,983 shares of the company's stock traded hands, compared to its average volume of 1,991,598. The company has a 50-day simple moving average of $123.24 and a two-hundred day simple moving average of $93.72. Insmed, Inc. has a 1-year low of $60.40 and a 1-year high of $149.08. The company has a market cap of $30.83 billion, a price-to-earnings ratio of -25.54 and a beta of 0.97. The company has a quick ratio of 6.33, a current ratio of 6.68 and a debt-to-equity ratio of 0.45.

Insmed (NASDAQ:INSM - Get Free Report) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.30) by ($0.40). The firm had revenue of $107.42 million during the quarter, compared to analyst estimates of $104.06 million. Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The firm's quarterly revenue was up 18.9% on a year-over-year basis. During the same period last year, the business posted ($1.94) earnings per share. Insmed has set its FY 2025 guidance at EPS. On average, analysts anticipate that Insmed, Inc. will post -4.56 earnings per share for the current year.

Analysts Set New Price Targets

INSM has been the subject of a number of research reports. HC Wainwright raised their price objective on Insmed from $90.00 to $120.00 and gave the stock a "buy" rating in a research report on Wednesday, June 11th. The Goldman Sachs Group raised their price objective on Insmed from $114.00 to $142.00 and gave the stock a "buy" rating in a research report on Wednesday, August 13th. Leerink Partners increased their target price on Insmed from $100.00 to $115.00 and gave the stock an "outperform" rating in a report on Tuesday, June 10th. Bank of America increased their target price on Insmed from $94.00 to $109.00 and gave the stock a "buy" rating in a report on Wednesday, June 11th. Finally, Morgan Stanley increased their target price on Insmed from $126.00 to $144.00 and gave the stock an "equal weight" rating in a report on Thursday, August 21st. Sixteen analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $139.86.

Insiders Place Their Bets

In other Insmed news, insider Orlov S. Nicole Schaeffer sold 76,520 shares of Insmed stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $145.45, for a total transaction of $11,129,834.00. Following the transaction, the insider directly owned 36,461 shares in the company, valued at approximately $5,303,252.45. The trade was a 67.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Sara Bonstein sold 58,400 shares of Insmed stock in a transaction dated Monday, July 21st. The stock was sold at an average price of $102.67, for a total value of $5,995,928.00. Following the transaction, the chief financial officer owned 73,505 shares in the company, valued at approximately $7,546,758.35. This represents a 44.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 335,097 shares of company stock worth $39,721,648 over the last three months. Insiders own 3.00% of the company's stock.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.